about
The Role of CC-Chemokines in the Regulation of AngiogenesisPhase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancerProof-of-concept study of monitoring cancer drug therapy with cerenkov luminescence imagingPulmonary toxicity related to systemic treatment of nonsmall cell lung cancer.Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer.Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence.The antitumor effect of tanshinone IIA on anti-proliferation and decreasing VEGF/VEGFR2 expression on the human non-small cell lung cancer A549 cell lineIn vitro the behaviors of metastasis with suppression of VEGF in human bone metastatic LNCaP-derivative C4-2B prostate cancer cell line.Clinical Challenges to Current Molecularly Targeted Therapies in Lung CancerEMMPRIN expression is required for response to bevacizumab therapy in HNSCC xenograftsShould progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?Pitfalls in pulmonary cytopathology.A synthetic compound, 1,5-bis(2-methoxyphenyl)penta-1,4-dien-3-one (B63), induces apoptosis and activates endoplasmic reticulum stress in non-small cell lung cancer cells.A new diaryl urea compound, D181, induces cell cycle arrest in the G1 and M phases by targeting receptor tyrosine kinases and the microtubule skeleton.Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status.
P2860
Q28077024-8679F647-6CE0-4CEE-8358-FD30C46E09ADQ33400938-323C0A31-7345-4D54-B6AF-0360AFA52D88Q34083326-3D0E5E11-38A3-4191-910A-2F69BC75D70AQ34626688-FDEC6FAA-CD33-43DA-8A00-D87994673CFDQ35014817-20633CC9-B245-4E9E-8E4A-A78A3A059247Q35076330-2ED23407-E590-4468-B868-E3160D113F51Q36363357-CA58DA42-EFDB-4059-A51C-512AA2737959Q36438808-7A726476-858A-49BA-8268-29CD4824832BQ36972377-F6CF6F4A-3BCB-41EE-8288-F63B86ACFD4DQ37105489-F641DEBB-CD99-424F-A7BD-BA4CCBB6C073Q37760357-8AD83FF7-D750-47FD-BEB6-85C18FC4CBD3Q37770470-2466AE42-4E55-465D-89DF-CFDFBB256D5DQ39424310-869AA935-2B3B-48D1-B51D-4377C17DD87FQ42818196-E9D186E9-4791-42FE-B5CD-7C491CFC38E0Q42976187-BBD0C34A-E06F-46B1-8BC8-604CBB1849E5
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Bevacizumab in non-small cell lung cancer.
@en
Bevacizumab in non-small cell lung cancer.
@nl
type
label
Bevacizumab in non-small cell lung cancer.
@en
Bevacizumab in non-small cell lung cancer.
@nl
prefLabel
Bevacizumab in non-small cell lung cancer.
@en
Bevacizumab in non-small cell lung cancer.
@nl
P2093
P1433
P1476
Bevacizumab in non-small cell lung cancer.
@en
P2093
Daniele Checcacci
Federica Di Costanzo
Francesca Mazzoni
Francesco Di Costanzo
Lorenzo Antonuzzo
Marinella Micol Mela
Matilde Saggese
P304
P356
10.2165/00003495-200868060-00002
P577
2008-01-01T00:00:00Z
P6179
1009116288